gefitinib has been researched along with npi 2358 in 1 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (npi 2358) | Trials (npi 2358) | Recent Studies (post-2010) (npi 2358) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 36 | 4 | 31 |
| Protein | Taxonomy | gefitinib (IC50) | npi 2358 (IC50) |
|---|---|---|---|
| Tubulin alpha-1A chain | Sus scrofa (pig) | 1.8 | |
| Tubulin beta chain | Sus scrofa (pig) | 1.8 | |
| RAF proto-oncogene serine/threonine-protein kinase | Homo sapiens (human) | 8.9 | |
| Mitogen-activated protein kinase 10 | Rattus norvegicus (Norway rat) | 6.8 | |
| Tubulin beta-2B chain | Bos taurus (cattle) | 2.4 | |
| Similar to alpha-tubulin isoform 1 | Bos taurus (cattle) | 2.4 | |
| Similar to alpha-tubulin isoform 1 | Bos taurus (cattle) | 2.4 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, H; Deng, M; Ding, Z; Dou, G; Hou, Y; Li, F; Li, W; Ma, M; Zhao, J | 1 |
1 other study(ies) available for gefitinib and npi 2358
| Article | Year |
|---|---|
In vitro and in vivo pharmacokinetic and pharmacodynamic study of MBRI-001, a deuterium-substituted plinabulin derivative as a potent anti-cancer agent.
Topics: Animals; Antineoplastic Agents; Blood Proteins; Cell Line, Tumor; Cytochrome P-450 Enzyme System; Deuterium; Diketopiperazines; Female; Half-Life; Humans; Inhibitory Concentration 50; Male; Mice; Mice, Inbred BALB C; Microsomes, Liver; Neoplasms; Protein Binding; Rats; Rats, Wistar; Tissue Distribution | 2018 |